Return to homepagePandemic Pact

ADDomer-COVID19 VLP vaccine to combat and defeat COVID19 outbreak

  • Funded by Elizabeth Blackwell Institute for Health Research
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Elizabeth Blackwell Institute for Health Research

  • Principal Investigator

    Unspecified Imre Berger

  • Research Location

    United Kingdom

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Professor Berger and team are using ADDomer, a novel rapid-response ultrastable synthetic virus-like particle (VLP) vaccine platform, to perform animal immunisation and virus neutralisation experiments using specially designed ADDomer-COVID19 candidate vaccines. The team plan to move towards a bona fide vaccine and into trials as soon as possible.